Claims for Patent: 6,391,633

Summary for Patent: 6,391,633

Title:	Production of erythropoietin by endogenous gene activation
Abstract:	The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO inhuman cells, and a method for the large technical production of EPO in human cells.
Inventor(s):	Stern; Anne (Penzberg, DE), Brandt; Michael (Iffeldorf, DE), Honold; Konrad (Penzberg, DE), Auer; Johannes (Penzberg, DE), Koll; Hans (Weilheim, DE)
Assignee:	Roche Diagnostics GmbH (Mannheim, DE)
Application Number:	09/463,380
Patent Claims:	1. An isolated human cell, which contains a copy of an endogenous EPO gene in operable linkage with a heterologous promoter active in the human cell and produces at least 200 ng EPO/10.sup.6 cells/24 h and wherein said endogenous EPO gene is not amplified and wherein the EPO gene has a signal peptide-coding sequence which codes for a signal peptide sequence wherein the sequence of the first 4 amino acids of said signal-peptide sequence is: wherein X.sub.1 is Gly or Ser, X.sub.2 is Ala, Val, Leu, Ile, Ser or Pro, and X.sub.3 is Pro, Arg, Cys or His, provided that X.sub.1 -X.sub.2 -X.sub.3 is not the sequence Gly-Val-His. 2. The isolated human cell according to claim 1, which produces 200-3000 ng EPO/10.sup.6 cells/24 h. 3. The isolated human cell produced by gene amplification from a cell according to claim 1, which contains several copies of an endogenous EPO gene, each in operative linkage with a heterologous promoter active in the human cell and produces at least 1000 ng EPO/10.sup.6 cells/24 h. 4. The isolated human cell according to claim 3, which produces 1000-25,000 ng EPO/10.sup.6 cells/24 h. 5. The isolated human cell according to claim 1 which it is an immortalized cell. 6. The isolated human cell according to claim 1, which can be cultured in serum-free medium. 7. The isolated human cell according to claim 1, which is selected from an HT 1080 cell, an HeLa S3 cell, or a Namalwa cell. 8. Human cell according to claim 1, wherein the activated endogenous EPO gene is under control of a viral promoter. 9. The isolated human cell according to claim 8, wherein the viral promoter is CMV promoter. 10. Human cell according to claim 1, wherein the amino acid sequence of the first 4 amino acids are: (a) Met-Gly-Ala-His, SEQ ID NO: 8 (b) Met-Ser-Ala-His, SEQ ID NO: 10 (c) Met-Gly-Val-Pro, SEQ ID NO: 12 or (d) Met-Ser-Val-His, SEQ ID NO: 14. 11. The isolated human cell according to claim 1, wherein the sequence of the first 4 amino acids of the signal peptide is Met-Ser-Ala-His SEQ ID NO: 10. 12. A method for the preparation of a human EPO-producing cell producing at least 200 ng EPO/10.sup.6 cells/24 h, comprising the steps: (a) preparation of human starting cells which contain at least one copy of an endogenous EPO gene, (b) transfection of the cells with a DNA construct comprising: (i) two flanking DNA sequences which are homologous to regions of the human EPO gene locus, to permit homologous recombination, (ii) a signal peptide-coding sequence which codes for a signal peptide sequence wherein the sequence of the first 4 amino acids of said signal-peptide coding sequence is: wherein X.sub.1 is Gly or Ser, X.sub.2 is Ala, Val, Leu, Ile, Ser or Pro, and X.sub.3 is Pro, Arg, Cys or His, provided that X.sub.1 -X.sub.2 -X.sub.3 is not the sequence Gly-Val-His, (iii) a positive selection marker gene, and (iv) a heterologous expression control sequence which is active in the human cell, (c) culturing the transfected cells under conditions in which a selection takes place for the presence of the positive selection marker gene, (d) analyzing the cells selected according to step (c), and (e) identification of the EPO-producing cells producing at least 200 ng/10.sup.6 cells/24 h, wherein the EPO gene is not amplified. 13. The method according to claim 12, wherein the homologous DNA sequences are selected from the region of the 5'-untranslated sequences, exon 1 and intron 1 of the EPO gene. 14. The method according to claim 13, wherein at least one of the DNA sequences which are homologous to regions of the human EPO gene site has a modified exon 1. 15. The method according to claim 13, wherein the selection marker gene is a neomycin phosphotransferase gene. 16. The method according to claim 13 wherein the DNA construct additionally comprises an amplification gene. 17. The method according to claim 16, wherein the amplification gene is a dihydrofolate reductase gene. 18. Method according to claim 17, wherein the amplification gene is a dihydrofolate reductase arginine-mutant. 19. The method for the preparation of a human EPO-producing cell according to claim 3 comprising the steps: (a) amplification of the EPO gene in the cell line of claim 1, (b) harvesting of EPO-producing cells which contain several copies of the endogenous EPO gene each in operable linkage with a heterologous expression control sequence. 20. The method according to claim 12 wherein the expression control sequence is a CMV promoter/enhancer. 21. The isolated human cell according to claim 1, wherein the EPO gene has a signal peptide-coding sequence which is different from the natural signal peptide-coding sequence. 22. A method for the preparation of a human EPO-producing cell producing at least 200 ng EPO/10.sup.6 cells/24 h, comprising the steps: (a) preparation of human starting cells which contain at least one copy of an endogenous EPO gene, (b) transfection of the human starting cells with plasmid p189 (DSM 1161) in linearized form, (c) culturing the transfected cells under conditions in which a selection takes place for the presence of the positive selection marker gene, (d) analyzing the cells selected according to step (c), and (e) identification of the EPO-producing cells producing at least 200 ng/10.sup.6 cells/24 h, wherein the EPO gene is not amplified.

Details for Patent 6,391,633

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-23